Pipeline

Discover our complex intranasal formulations and advanced drug-delivery solutions for chronic respiratory diseases and central nervous system disorders.

We develop a platform of drug-enabling solutions. Those long-acting intranasal solid dosage forms are designed to ensure a prolonged and targeted drug-delivery in chronic respiratory and Central Nervous System diseases.

DIA01-R
 — Indicated for moderate to severe persistent allergic rhinitis. Resorbable fluticasone propionate-eluting insert delivering local treatment over 6 months
DIA02-S
 — Indicated for Chronic Rhinosinusitis without polyps. Resorbable fluticasone propionate-eluting insert delivering local treatment over 12 months
DIA03-NTB
 — Indicated for resistant schizophrenia. Exploratory program using nose to brain route to deliver active compounds directly to the brain.
THERAPEUTIC AREAS

Where current treatments fall short

Dianosic targets two therapeutic areas with massive unmet medical needs: chronic respiratory diseases and central nervous system disorders.

Respiratory diseases

  • 1.4 B patients suffer from persistent allergic rhinitis worldwide¹
  • 900 M patients impacted by chronic rhinosinusitis²
  • 85% of allergic rhinitis patients are not compliant with their treatment³
  • 20–25% of CRS patients do not respond to first-line treatment⁴

CNS / Nose-to-Brain

  • 35 M patients affected by schizophrenia and Parkinson’s disease⁵
  • Major drug-delivery barriers (blood-brain barrier, hepatic first-pass metabolism) limit treatment efficacy
  • Patient adherence remains a critical challenge in CNS chronic therapies
  • Major drug-delivery barriers (blood-brain barrier, hepatic first-pass metabolism) limit treatment efficacy

<